热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Brilliant Violet 421™ anti-mouse CD45 Antibo
产品名称：
Brilliant Violet 421™ anti-mouse CD45 Antibo
产品类别：
抗体
产品编号：
103133
产品应用：
103133
[价格]
规格 价格 库存
125µL ￥ 2184 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. For immunofluorescent staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5,?immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  11. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Zahr A, et al. 2016. Nat Commun. 7:10363. PubMed
  2. Naito H, et al. 2020. Nature Protocols. 15(3):1066-1081. PubMed
  3. Schlecht A, et al. 2021. Int J Mol Sci. 22:. PubMed
  4. Cullis J, et al. 2017. Cancer Immunol Res. 5:182. PubMed
  5. Ulland TK et al. 2017. Cell. 170(4):649-663 . PubMed
  6. Barrow AD et al. 2018. Cell. 172(3):534-548 . PubMed
  7. Galán-Díez M, et al. 2022. Cancer Discov. . PubMed
  8. Sharma GP, et al. 2021. PLoS One. 16:e0259042. PubMed
  9. Deng J, et al. 2021. JCI Insight. 6:146133. PubMed
  10. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  11. Kurelac I, et al. 2019. Nat Commun. 10:903. PubMed
  12. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  13. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  14. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  15. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  16. Karlsson J, et al. 2021. Adv Funct Mater. 31:. PubMed
  17. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  18. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  19. Song WM, et al. 2018. J Exp Med. 215:745. PubMed
  20. Shmeleva EV, et al. 2019. Front Immunol. 10:1780. PubMed
  21. Bratti M, et al. 2022. Front Immunol. 13:1029759. PubMed
  22. Cui Z, et al. 2022. Bone Res. 10:58. PubMed
  23. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  24. Webster HC, et al. 2020. J Immunol Methods. 112702:477. PubMed
  25. Crncec I, et al. 2018. Mol Oncol. 12:514. PubMed
  26. Kobayashi H, et al. 2020. STAR Protoc. 1:100078. PubMed
  27. Schlecht A, et al. 2021. Front Cell Dev Biol. 8:618598. PubMed
  28. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  29. Bell BJ, et al. 2022. Brain Behav Immun Health. 23:100478. PubMed
  30. Helm M, et al. 2022. Life (Basel). 12:. PubMed
  31. Nishiga Y, et al. 2022. Nat Cancer. 3:1351. PubMed
  32. Suter EC, et al. 2021. Cell Reports. 36(8):109587. PubMed
  33. Mittal S, et al. 2016. Stem Cell Reports. 7:583-590. PubMed
  34. Saika A, et al. 2020. FASEB Bioadv. 2:59. PubMed
  35. Chu C, et al. 2016. Dis Model Mech. 9: 473-481. PubMed
  36. Hagan AS, et al. 2020. Development. 147:00:00. PubMed
  37. Kramann R, et al. 2018. JCI Insight. 3. PubMed
  38. Parlet CP, et al. 2019. Cell Rep. 27:187. PubMed
  39. Jiang H, et al. 2021. Oncoimmunology. 10:1943180. PubMed
  40. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  41. Haase C, et al. 2022. Nat Methods. 19:1622. PubMed
  42. Pan YC, et al. 2021. Mol Ther Oncolytics. 20:175. PubMed
  43. Li J, et al. 2020. Elife. 9:00. PubMed
  44. Li Q, et al. 2019. Front Cell Neurosci. 12:520. PubMed
  45. Mamedov MR, et al. 2018. Immunity. 48:350. PubMed
  46. Agalave NM, et al. 2021. Front Immunol. 12:642420. PubMed
  47. Katara GK, et al. 2020. Mol Oncol. 0.729861111. PubMed
  48. de Lucía Finkel P, et al. 2021. Sci Rep. 11:12233. PubMed
  49. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
  50. Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed
  51. Boeck M, et al. 2020. Glia. 1859:68. PubMed
  52. Deczkowska A, et al. 2017. Nat Commun. 8:717. PubMed
  53. Carbone C, et al. 2021. J Immunother Cancer. 9:. PubMed
  54. Aktories P, et al. 2022. Cell Rep Methods. 2:100260. PubMed
  55. Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed
  56. Bersini S, et al. 2020. Life Sci Alliance. 3:e201900623. PubMed
  57. Durré T, et al. 2018. Nat Commun. 9:5178. PubMed
  58. Perdigoto AL, et al. 2022. JCI Insight. 7:. PubMed
  59. Chuang CH, et al. 2020. Cancer Research. 81(3):567-579. PubMed
  60. Ma Z, et al. 2022. Methods Mol Biol. 2471:49. PubMed
  61. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  62. Goh W, et al. 2020. Cell Rep. 33:108285. PubMed
  63. Dahlgren MW et al. 2019. Immunity. 50(3):707-722 . PubMed
  64. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  65. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  66. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  67. Zhang P, et al. 2021. J Neuroinflammation. 18:215. PubMed
  68. Yi H, et al. 2021. Front Immunol. 12:719189. PubMed
  69. Wieghofer P, et al. 2021. EMBO J. 40:e105123. PubMed
  70. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  71. Zhang X, et al. 2021. Front Pharmacol. 12:629513. PubMed
  72. Ben-Yehuda H, et al. 2021. Mol Neurodegener. 16:39. PubMed
  73. Wakabayashi T et al. 2018. Cell stem cell. 22(3):384-397 . PubMed
  74. Mao W, et al. 2019. J Immunother Cancer. 0.484027778. PubMed
  75. Zheng X, et al. 2020. Int J Cancer. 146:1730. PubMed
  76. Hoover AR, et al. 2022. Clin Transl Med. 12:e937. PubMed
  77. Zhang Y, et al. 2021. Commun Biol. 344:4. PubMed
  78. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  79. Glodde N et al. 2017. Immunity. 47(4):789-802 . PubMed
  80. Meng Michelle Xu et al. 2017. Immunity. 47(2):363-373 . PubMed
  81. Sü? P, et al. 2020. Cell Reports. 30(12):4082-4095. PubMed
  82. Ombrato L, et al. 2021. Nat Protoc. 16:872. PubMed
  83. Siolas D, et al. 2021. Cell Reports. 36(8):109578. PubMed
  84. Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed
  85. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  86. Celorrio M, et al. 2022. Acta Neuropathol Commun. 10:10. PubMed
  87. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  88. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  89. Hu B, et al. 2020. J Clin Invest. 130:3483. PubMed
  90. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
  91. Nishimura T, et al. 2020. Cell Stem Cell. 28(1):141-149.e3. PubMed
  92. Usui-Ouchi A, et al. 2020. Proc Natl Acad Sci U S A. 28297:117. PubMed
  93. Boddupalli CS, et al. 2022. Elife. 11:. PubMed
  94. Palma A, et al. 2022. Front Cell Dev Biol. 10:841548. PubMed
  95. Omori S, et al. 2020. Cell Metabolism. 32(5):814-828.e6. PubMed
  96. Zheng H, et al. 2021. Frontiers in Immunology. 12:645100. PubMed
  97. Liu Q, et al. 2016. Cell Death Dis. 1.93125. PubMed
  98. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
RRID
AB_10899570 (BioLegend Cat. No. 103133) AB_2562559 (BioLegend Cat. No. 103134)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线